Johnson & Johnson's Janssen Pharmaceuticals has entered into a deal with the African Vaccine Acquisition Trust (AVAT) that will enable up to 400 million doses of the company's single-shot vaccine candidate to be made available to African Union member states.
Per the deal, Janssen will make up to 220 million doses of its vaccine candidate available to African Union's 55 member states, with delivery beginning in the third quarter of 2021. AVAT also has the potential to order an additional 180 million doses, for a combined total of up to 400 million doses through 2022.
The availability of the vaccine candidate is subject to its successful authorization by the national regulatory authorities of the AU member states.
Aspen Pharmacare of South Africa will support the vaccine shipments to the African Union.
Read the press release